

MetaboCure - Restoring Life to Cancer Cachexia Patients Dror Melamed A

Company name MetaboCure Ltd. \* Website [www.metabocure.com](http://www.metabocure.com) \* CEO name Ronen Sarusi\* \* Select a CATEGORY: Biotech

“Rewriting Biology In Vivo: The Age of Cellular Reprogramming.”

: Cancer cachexia is a syndrome of irreversible wasting in the terminally ill patients. It is the most common manifestation of the advanced malignant disease, leading to death (over 80% of aggressive cancers patients suffer from cachexia). Cachexia is responsible for 20% of total cancer deaths (1.9M deaths annually). Currently, there is no cure for cachexia. We have demonstrated and validated that down regulation of the hepatic transcription factor HNF4- $\alpha$ , a master regulator of hepatic metabolic genes, has a key role in disrupting normal metabolism, leading to tumor progression and resulting in cachexia. MetaboCure develops Nuforal™ - an mRNA therapy encapsulated in lipid nanoparticles (LNP), designed to restore HNF4- $\alpha$ . It addresses the root cause of cachexia, offering a holistic renewal of the disrupted metabolic state. The urgent unmet need, the solid mechanism of action, the proposed solution and the substantial market opportunity positions Nuforal as a transformative therapeutic opportunity to redefine the treatment of cachexia and improve outcomes in advanced cancer patients.